Boston Scientific Corporation (NYSE:BSX) reported Q2 2017 earnings this Morning, coming in at $0.32 per share, beating Wall Street’s estimates of $0.31 per Share. Revenue for the quarter came in at $2.26 billion beating analyst estimates of $2.21 billion
Analyst Coverage For Boston Scientific Corporation (NYSE:BSX)
These are 6 Hold Ratings, 15 Buy Ratings .
The current consensus rating for Boston Scientific Corporation (NYSE:BSX) is Buy (Score: 2.71) with a consensus target price of $29.91 , a potential (9.07% upside)Recent Insider Trading for Boston Scientific Corporation (NYSE:BSX)
- On 7/11/2017 Daniel J Brennan, CFO, sold 92,158 with an average share price of $27.48 per share and the total transaction amounting to $2,532,501.84.
- On 7/3/2017 Timothy A Pratt, EVP, sold 10,000 with an average share price of $27.87 per share and the total transaction amounting to $278,700.00.
- On 6/29/2017 Michael P. Phalen, EVP, sold 15,500 with an average share price of $28.02 per share and the total transaction amounting to $434,310.00.
- On 6/9/2017 David A Pierce, SVP, sold 13,562 with an average share price of $28.00 per share and the total transaction amounting to $379,736.00.
- On 6/2/2017 David A Pierce, SVP, sold 2,972 with an average share price of $27.70 per share and the total transaction amounting to $82,324.40.
- On 6/1/2017 Timothy A Pratt, EVP, sold 10,000 with an average share price of $27.13 per share and the total transaction amounting to $271,300.00.
Recent Trading for Boston Scientific Corporation (NYSE:BSX) Shares of Boston Scientific Corporation closed the previous trading session at 27.14 down -0.28 -1.04% with 4,554,391 shares trading hands.